Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 8/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581236 | 0.77 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6799024 | 0.74 | CCKBR (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6792780 | 0.60 | CYP2C19 (0.39) | — | |
| SCHEMBL6792777 | 0.60 | CYP2C19 (0.39) | — | |
| SCHEMBL4993119 | 0.59 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4987907 | 0.59 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4414659 | 0.59 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413310 | 0.59 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4991055 | 0.58 | OPRL1 (0.43) | OPRL1OPRM1OPRK1SCN9ATRPA1 | |
| SCHEMBL6798996 | 0.58 | CYP4F2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | claimed |
| EP-1268434-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | claimed |
| WO-2001074784-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1268434-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2001074784-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.